Leflunomide for inflammatory arthritis in end-stage renal disease on peritoneal dialysis: a pharmacokinetic and pharmacogenetic study.

@article{Russo2013LeflunomideFI,
  title={Leflunomide for inflammatory arthritis in end-stage renal disease on peritoneal dialysis: a pharmacokinetic and pharmacogenetic study.},
  author={Paul Anthony John Russo and Michael David Wiese and Malcolm D. Smith and Michael John Ahern and Jeffrey A. J. Barbara and E. Michael Shanahan},
  journal={The Annals of pharmacotherapy},
  year={2013},
  volume={47 3},
  pages={e15}
}
OBJECTIVE To study the pharmacokinetics and pharmacogenetics of leflunomide and document its efficacy and safety in the treatment of inflammatory arthritis in a patient with end-stage renal disease (ESRD) who was on peritoneal dialysis. CASE SUMMARY Therapy for a 78-year-old man with ESRD who required peritoneal dialysis was started with leflunomide 10 mg/day for psoriatic arthritis. The dosage was increased to 20 mg/day after 3 months. Monitoring was continued until the patient's unexpected… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 3 times over the past 90 days. VIEW TWEETS

References

Publications referenced by this paper.
Showing 1-10 of 22 references

Similar Papers

Loading similar papers…